Scarica l'app Stockscreener
25.04
0.93%
0.23
Dopo l'orario di chiusura:
25.04
Pacira Biosciences Inc Borsa (PCRX) Ultime notizie
Investors Who Lost Money with Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Should Contact the Shareholders Foundation in Connection with Lawsuit - Newswire.com
Is now a turning point for Pacira BioSciences Inc.July 2025 Patterns & Risk Controlled Daily Plans - Newser
Can technical indicators confirm Pacira BioSciences Inc.’s reversalJuly 2025 Setups & Safe Capital Allocation Plans - Newser
Natixis Advisors LLC Invests $327,000 in Pacira BioSciences, Inc. (NASDAQ:PCRX) - Defense World
Volatility clustering patterns for Pacira BioSciences Inc.July 2025 Rallies & AI Powered Market Entry Strategies - Newser
Will Pacira BioSciences Inc. stock recover after recent dropWeekly Trade Analysis & Growth Oriented Trading Recommendations - Newser
Advanced analytics toolkit walkthrough for Pacira BioSciences Inc.2025 Key Lessons & AI Driven Stock Price Forecasts - Newser
Pacira BioSciences Inc. stock trendline breakdownJuly 2025 Catalysts & Safe Investment Capital Preservation Plans - Newser
Is Pacira BioSciences Inc. building a consolidation baseFree Day Trading Signals With High Precision - Newser
Trend analysis for Pacira BioSciences Inc. this weekLong Term Stock Growth Plan Suggestions - Newser
Real time alert setup for Pacira BioSciences Inc. performanceWeekly Setup Summary for Risk Controlled Trades - Newser
Bronstein, Gewirtz & Grossman, LLC Is Investigating Pacira BioSciences, Inc. (PCRA) And Encourages Investors to Connect - ACCESS Newswire
Exit strategy if you’re trapped in Pacira BioSciences Inc.Safe Investment Ideas with Growth Upside - Newser
Signal strength of Pacira BioSciences Inc. stock in tech scannersSupport and Resistance Zone Summary Chart - Newser
How Pacira BioSciences Inc. stock performs during market volatilityAI Enhanced Strategy for Portfolio Growth - Newser
Pacira BioSciences Inc (NASDAQ: PCRX) Yet To Convince Analysts? - stocksregister.com
Will a bounce in Pacira BioSciences Inc. offer an exitEntry and Exit Strategy for Swing Traders - Newser
Detecting price anomalies in Pacira BioSciences Inc. with AIFundamental Analysis for Value Stock Selection - Newser
Earnings visualization tools for Pacira BioSciences Inc.Free Short Term Buy Zone Stock Alerts - Newser
Order flow analysis tools used on Pacira BioSciences Inc.Free Real Profit Trade Plan Suggestions - Newser
Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Pacira announces layoffs due to efficiencies in Exparel production - MSN
Doma Perpetual's 5.7% Stake in Pacira Biosciences: A Catalyst for Governance Change or Strategic Alignment? - AInvest
Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $25.75 - Defense World
Doma Perpetual Discloses 5.7% Stake in Pacira Biosciences - MarketScreener
Can machine learning forecast Pacira BioSciences Inc. recoveryRisk Balanced Picks for Safer Trading - Newser
Pacira BioSciences, Inc. (NASDAQ:PCRX) Position Lifted by Zurcher Kantonalbank Zurich Cantonalbank - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q2 2025 Earnings Call Transcript - Insider Monkey
Can Pacira BioSciences Inc. rally from current levelsStrong Buy Opportunity with Volume Support - Newser
Pacira Biosciences Q2 Earnings Call Highlights Growth and Strategy Amid Challenges - AInvest
Pacira BioSciences Reports Q2 2025 Results: EPS of -$0.11 Misses Estimates, Revenue at $181.1 Million Below Expectations - AInvest
Pacira BioSciences Reports Q2 2025 Financial Results: $181.1M Revenue, Net Loss of $4.8M - AInvest
New Product Launches: Will They Boost Pacira BioSciences Inc. Stock in 2025Momentum Entry Alerts with Risk Control - Newser
Pacira Biosciences shares rise 2.09% intraday after Q2 revenue beat expectations. - AInvest
Pacira Biosciences Q2 Non-GAAP Earnings Fall, Revenue Rises; Updates 2025 Sales Forecast - MarketScreener
Pacira BioSciences Posts Strong Q2 Growth, Boosts 2025 Revenue Guidance - AInvest
Pacira BioSciences (PCRX) Bolsters Growth with Strategic Moves - GuruFocus
Pacira BioSciences Inc (PCRX) Q2 2025 Earnings Call Highlights: Strong Growth in EXPAREL Sales ... - Yahoo Finance
Pacira BioSciences Inc (PCRX) Q2 2025 Earnings Call Highlights: Strong Growth in EXPAREL Sales ... By GuruFocus - Investing.com Canada
Pacira BioSciences' Q2 2025: Contradictions Surface on EXPAREL Market Access, Sales, and Margins - AInvest
Pacira BioSciences Q2 2025 Earnings Call Transcript: Key Takeaways - AInvest
Pacira BioSciences Inc (PCRX) Q2 2025 Earnings Call Highlights: - GuruFocus
Pacira BioSciences Q2 2025 Earnings Call Transcript - MarketBeat
Pacira BioSciences Reports Q2 2025 Financial Results - TipRanks
Decoding Pacira BioSciences Inc (PCRX): A Strategic SWOT Insight - GuruFocus
Pacira BioSciences: A Strategic Turnaround in the Opioid-Alternative Sector - AInvest
4.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):